In 2009, the School established the Centre for Cancer and Inflammation Research (CCIR), which sets out to search for the causes of cancer and inflammatory conditions as well as novel therapeutic strategies by combining Chinese medicine and modern scientific technology, with the aim of pursuing innovative research in contributing to the health of human kind.
Riding on the rapid development of Chinese medicine, the Centre concentrates its research on the most commonly occurring types of cancers and inflammatory conditions in Hong Kong, such as lung cancer, breast cancer, colorectal cancer and rheumatoid arthritis, by leveraging on the experts, resources and facilities of the School as well as the strengths of collaborative institutions locally and abroad. The Centre is honoured to have invited a number of renowned scholars to serve as academic advisors to jointly set up a platform for international collaborations on anti-cancer and anti-inflammation research.
Welcome to visit homepage of Shum Yiu Foon Sum Bik Chuen Memorial Centre for Cancer and Inflammation Research(CCIR) Through this website, we hope to provide you with more information and resource that will assist you in acquiring knowledge about common cancerous and inflammatory diseases as well as getting to know our institute and also share some data service in the meanwhile.
The CCIR is to function as a unit to integrate academic resource (infrastructure and expertise) and industrial network to facilitate development of innovative bioinformatics approach to drug discovery, novel biological reagents, unique therapeutic agents, advanced bio-imaging modalities and new biomaterials for diagnosis, prevention and treatment toward Phase-I clinical trials and commercialization incommon cancerous and inflammatory diseases.
You are warmly welcomed to join or collaborate with us. The CCIR can provide you a platform to show your intellect and create novel thoughts.
Director of the Centre for Cancer Inflammation Research
Dean & Chair Professor of School of Chinese Medicine
September 1st, 2012